Back to Search
Start Over
The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma
- Source :
- Europe PubMed Central
- Publication Year :
- 2015
-
Abstract
- For patients with diffuse large B cell lymphoma without the involvement of the CNS, the addition of rituximab to standard chemotherapy has significantly improved survival. In this single-center, retrospective analysis, a total of 81 primary CNS lymphoma (PCNSL) patients treated in our institution between 2000 and 2011 were included. Beside first-line chemotherapy with or without rituximab, we evaluated the impact of age (≤/>60 years), autologous stem cell transplantation (ASCT +/-), and other factors upon overall survival (OS) and progression-free survival (PFS). In patients treated with rituximab (n = 27), 3-year OS was 77.8 % (95 % confidence interval (CI) 62-93 %). In contrast, in patients treated without rituximab (n = 52), 3-year OS was only 39.9 % (CI 27-53 %, Fig. 1). The difference in OS was significant in the univariate (p = 0.002) as well as in the multivariate analysis (p = 0.049, hazard ratio (HR) = 0.248). Patients ≤60 years of age (n = 28) had a 3-year OS of 78.2 % (CI 63-94 %); in patients >60 years (n = 51), 3-year OS was 38.7 % (CI 25-52 %). Patients who received high-dose therapy and ASCT had a 3-year OS of 85.2 % (CI 72-99 %), and 65.1 % were alive up to the time of analysis (range 9-131 months). Without ASCT, median OS was only 16 months (CI 11-21) and 3-year OS was 35.2 % (CI 22-48 %). Age and ASCT were significantly associated with better OS in univariate (p = 0.002 and p
- Subjects :
- Adult
Male
medicine.medical_specialty
Lymphoma
medicine.medical_treatment
Hematopoietic stem cell transplantation
Gastroenterology
Transplantation, Autologous
Central Nervous System Neoplasms
Autologous stem-cell transplantation
Internal medicine
medicine
Humans
Survival analysis
Aged
Retrospective Studies
Aged, 80 and over
Chemotherapy
Dose-Response Relationship, Drug
business.industry
Hazard ratio
Age Factors
Hematopoietic Stem Cell Transplantation
Hematology
General Medicine
Middle Aged
medicine.disease
Combined Modality Therapy
Survival Analysis
Surgery
Rituximab
Female
business
Diffuse large B-cell lymphoma
medicine.drug
Subjects
Details
- ISSN :
- 14320584
- Volume :
- 94
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Annals of hematology
- Accession number :
- edsair.doi.dedup.....fec09342097904b8c30569ffc6008de8